In a series of 42 positive sera, anti-mitochondrial type M5 antibodies (AMA-M5) were found most frequently in patients with SLE (24) and SLE-like syndromes. Patients with AMA-M5 displayed a higher prevalence of thrombocytopenia, thrombosis, biological false positive seroreactions for syphilis, lupus-like anticoagulant activity and anti-cardiolipin antibodies in comparison with a group of 43 SLE AMA-M5 negative patients. The strong association between anti-phospholipid and AMA-M5 antibodies cannot be explained entirely by cross-reactivity between these two groups of antibodies, as indicated by absorption experiments and studies using affinity purified antibody preparations. However, cardiolipin liposomes were able to reduce partially the titres of AMA-M5 sera, suggesting that a small population of AMA-M5 antibodies exists that cross-reacts with cardiolipin. The existence of this population was further substantiated by our demonstration that an IgM monoclonal antibody, from a patient with Waldenström's macroglobulinaemia, displayed both anti-cardiolipin and AMA-M5 activity, and AMA-M5 activity was completely inhibited by cardiolipin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1542609PMC

Publication Analysis

Top Keywords

anti-mitochondrial type
8
anti-cardiolipin antibodies
8
ama-m5
8
ama-m5 antibodies
8
ama-m5 activity
8
antibodies
6
type anti-cardiolipin
4
antibodies autoimmune
4
autoimmune disorders
4
disorders studies
4

Similar Publications

Background: Giant cell (gc)-enriched glioblastoma (gcGB) represents a distinct histological variant of isocitrate dehydrogenase wild-type adult-type glioblastoma with notable enlarged mono- or multinuclear tumor cells. While some studies suggest a survival advantage for gcGB patients, the underlying causes remain elusive. GcGBs are associated with TP53 mutations, and gcs were shown to accumulate DNA double-strand breaks and show deficient mitosis, potentially triggering cellular senescence programs.

View Article and Find Full Text PDF

To analyze the positivity rate and titer of antinuclear antibody (ANA), as well as nuclear pattern and target antigen of ANA in healthy pregnant women during early pregnancy in Qingdao area. A prospective cohort study design was used to include a total of 9 528 healthy pregnant women registered at the Women and Children's Hospital Affiliated to Qingdao University from March 2023 to June 2024.Indirect immunofluorescence assay (IIF) was used to detect ANA, its titer and cell staining pattern.

View Article and Find Full Text PDF

Identification of a novel PDC-E2 epitope in primary biliary cholangitis: Application for engineered Treg therapy.

J Autoimmun

December 2024

Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Department of Immunology, University of Washington, Seattle, WA, USA. Electronic address:

Article Synopsis
  • Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease primarily affecting small bile ducts, with limited treatment options and a reliance on liver transplants in severe cases.
  • Researchers studied T cell responses to a specific protein (PDC-E2) linked to PBC, focusing on a common genetic marker (HLA Class II DRB4∗01:01) found in many patients.
  • They discovered unique T cell receptors (TCRs) that can target a new PDC-E2 epitope, leading to the development of engineered regulatory T cells (EngTreg) that could help suppress harmful immune responses in PBC patients, offering potential for new therapies.
View Article and Find Full Text PDF

Mitochondrial Proteins as Metabolic Biomarkers and Sites for Therapeutic Intervention in Primary and Metastatic Cancers.

Mini Rev Med Chem

July 2024

Laboratorio de Control Metabólico, Carrera de Medicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Los Reyes Ixtacala, Hab Los Reyes Ixtacala Barrio de los Árboles/Barrio de los Héroes, Tlalnepantla, 54090, México.

Accelerated aerobic glycolysis is one of the main metabolic alterations in cancer, associated with malignancy and tumor growth. Although glycolysis is one of the most studied properties of tumor cells, recent studies demonstrate that oxidative phosphorylation (OxPhos) is the main ATP provider for the growth and development of cancer. In this last regard, the levels of mRNA and protein of OxPhos enzymes and transporters (including glutaminolysis, acetate and ketone bodies catabolism, free fatty acid β-oxidation, Krebs Cycle, respiratory chain, phosphorylating system- ATP synthase, ATP/ADP translocator, Pi carrier) are altered in tumors and cancer cells in comparison to healthy tissues and organs, and non-cancer cells.

View Article and Find Full Text PDF

Cluster analysis of clinical phenotypes in idiopathic inflammatory myopathy patients complicated with cardiac involvement.

Clin Rheumatol

July 2024

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuai-Fu-Yuan, Dongcheng District, Beijing, 100730, China.

Article Synopsis
  • - The study aimed to classify idiopathic inflammatory myopathy patients with cardiac involvement (IIM-CI) into two distinct categories based on their clinical characteristics and examine their outcomes over several years at Peking Union Medical College Hospital.
  • - A total of 88 patients were analyzed, resulting in two categories: Category I showed significant heart issues and higher rates of arrhythmia and pulmonary hypertension, while Category II had more systemic symptoms and skeletal muscle weakness.
  • - The findings indicated that heart failure was the leading cause of death for Category I patients, whereas severe pneumonia was the main cause of death for those in Category II, highlighting the differing health risks associated with each category.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!